Ascletis Reveals Promising Results of Obesity Treatments at ObesityWeek® 2025

Ascletis Presents Efficacy and Safety Data on ASC30 at ObesityWeek® 2025

Ascletis Pharma Inc., a biopharmaceutical company based in Hong Kong, recently unveiled groundbreaking insights from their Phase Ib studies concerning their obesity treatment candidates at ObesityWeek 2025 in Atlanta, Georgia. The studies focus on the ASC30 oral tablet and injection formulations, alongside combinations of their innovative agents ASC31 and ASC47. With obesity being a significant global health concern, these findings are a crucial step forward in the ongoing search for effective treatments.

Positive Outcomes from ASC30 Studies

The first key component, the ASC30 oral tablet, showed impressive results in a Phase Ib trial with a remarkable reduction in mean body weight. The study revealed an average loss of up to 6.5% when adjusted against placebo, with some participants even achieving up to 9.3% weight loss. Importantly, the treatment demonstrated a solid safety profile, with primarily mild to moderate gastrointestinal issues reported, which is typically expected in weight-loss therapies.

For the ASC30 subcutaneous injection, the results were equally promising, exhibiting a half-life of 46 days for the treatment formulation and 75 days for the maintenance version. These lengthy half-lives bolster the potential of ASC30 as a convenient option for chronic weight management, allowing for less frequent dosing, ultimately enhancing patient compliance and quality of life.

Insights Into New Peptide Combinations

Furthermore, the combination treatment of ASC31 and ASC47 provides another layer of innovation. This regimen not only outshined the effects of standard treatments like tirzepatide but also showcased its ability to support both weight loss and muscle preservation in diet-induced obesity (DIO) mouse studies. The results indicated a 44.8% weight reduction when using ASC31 and ASC47 together, significantly outperforming other treatments, emphasizing the potential dual action of these peptides by targeting relevant pathways in the body.

Technological Innovations Behind the Pipeline

The advancements presented by Ascletis are rooted in their proprietary technologies, namely, the Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and the Ultra-Long Acting Platform (ULAP). These technologies enhance the exploratory capabilities in drug development, allowing for a rich pipeline of candidates that effectively cater to the needs of patients dealing with obesity.

Jinzi Jason Wu, Ph.D., the company's Chairman and CEO, expressed confidence in the ongoing clinical developments, emphasizing their strategic collaborations aimed at addressing the global obesity crisis. Wu stated, "We remain determined to position Ascletis to meet the global needs of patients battling obesity as we advance our candidate pipeline and explore new partnerships."

Future Perspectives

The findings presented at ObesityWeek 2025 showcase Ascletis' commitment to innovating in the space of metabolic disease therapeutic development. The compelling data from their Phase Ib trials support their initial hypothesis that both ASC30 and the combined peptide therapies can significantly impact obesity management, potentially leading to better health outcomes for millions worldwide. As Ascletis continues its research, the landscape of obesity treatment may soon experience invaluable changes, paving the way for more accessible and effective therapies for individuals struggling with this pervasive issue.

For further details on the results presented, feel free to visit the official Ascletis website.